Breast Cancer

HER2DX demonstrated the ability to select patients who are more likely to achieve disease control with anti-HER2 standard of care in the CLEOPATRA trial.

Treatment with RLY-2608 plus fulvestrant appears well tolerated among patients with PI3Kα-mutated breast cancer in the ReDiscover trial.

The OPHELIA trial assessed the efficacy and safety of olaparib plus trastuzumab in HER2-positive advanced breast cancer with germinal BRCA mutations.

The PREFERABLE-EFFECT study found that supervised resistance and aerobic exercise were associated with reduced fatigue in patients with metastatic breast cancer.

Data from the DESTINY-Breast06 trial support the FDA breakthrough therapy designation for T-DXd in HR–positive, HER2-low, or HER2-ultralow breast cancer.

Phase 1 AC699-001 results evaluating the safety and efficacy of AC699 in patients with breast cancer subtypes support the Fast Track designation.

Findings from a population-based study suggest patients with POI may need genetic counseling regarding future risk of reproductive cancers.

Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma.

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

Retrospective analysis found that cryoablation was associated with infrequent AEs and low recurrence rates among patients with breast cancer.